Erdosteine information from DrugsUpdate
P - Caution when used during pregnancy
L - Caution when used during lactation
Erdosteine is a mucolytic. Specifically it is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine contains two blocked sulfhydryl groups which are released following first-pass metabolism. The three active metabolites exhibit mucolytic and free radical scavenging activity. Erdosteine modulates mucus production and viscosity and increases mucociliary transport, thereby improving expectoration. It also exhibits inhibitory activity against the effects of free radicals produced by cigarette smoke.
Clinical studies in patients with chronic obstructive lung disease have demonstrated the efficacy and tolerability of erdosteine.Erdosteine 300 mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than bromhexine 30 mg twice daily.
Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo.
Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild. The LD50 is very high, 3,500-5,000 mg/kg.
Pharmacodynamics
Pharmacokinetics
Erdosteine contains two sulfhydryl groups, which are freed after metabolic transformation in the liver. The liberated sulfhydryl groups break the disulphide bonds, which hold the glycoprotein fibres of mucus together. This makes the bronchial secretions more fluid and enhances elimination.
Absorption
Rapid absorption after oral admin.
Distribution
Protein binding: 64.5%.
Metabolism
Undergoes 1st-pass metabolism to form an active metabolite, N-thiodiglycolyl-homocysteine.
Excretion
Elimination half-life: About 1.46 hr (erdosteine), and about 1.62 hr (metabolite). Mainly via the urine, as metabolites.
Erdosteine Indications / Erdosteine Uses
Information Not Available
Erdosteine Adverse Reactions / Erdosteine Side Effects
Epigastralgia, nausea, vomiting, loose stools, spasmodic colitis, headache.
Precautions
Information Not Available
Special Precautions
Pregnancy, lactation
Other Drug Interactions
Information Not Available
Other Interactions
Information Not Available
Dosage
Oral
Mucolytic
Adult: 300 mg bid. Max duration: 10 days
Food(before/after)
Information Not Available
List of Contraindications
Erdosteine and Pregnancy
Caution when used during pregnancy
Erdosteine and Lactation
Caution when used during lactation
Erdosteine and Children
Information Not Available
Erdosteine and Geriatic
Information Not Available
Erdosteine and Other Contraindications
Active peptic ulcer
Storage
Oral
Store below 25°C
Lab interference
Oral
Store below 25°C
FOLLOW US:
